Trial Profile
A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs LAE 001 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Novartis
- 19 Jul 2016 Status changed from completed to discontinued.
- 05 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 04 Nov 2014 Planned End Date changed from 1 Jan 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov